• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Commun Biol . Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2

tetano

Editor, Senior Moderator
Commun Biol


. 2021 Apr 12;4(1):475.
doi: 10.1038/s42003-021-02030-3.
Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2


Kushal Suryamohan[SUP] #[/SUP][SUP] 1 [/SUP], Devan Diwanji[SUP] #[/SUP][SUP] 2 3 [/SUP], Eric W Stawiski[SUP] #[/SUP][SUP] 1 [/SUP], Ravi Gupta[SUP] 4 [/SUP], Shane Miersch[SUP] 5 [/SUP], Jiang Liu[SUP] 6 [/SUP], Chao Chen[SUP] 5 [/SUP], Ying-Ping Jiang[SUP] 6 [/SUP], Frederic A Fellouse[SUP] 7 [/SUP], J Fah Sathirapongsasuti[SUP] 1 [/SUP], Patrick K Albers[SUP] 8 [/SUP], Tanneeru Deepak[SUP] 4 [/SUP], Reza Saberianfar[SUP] 7 [/SUP], Aakrosh Ratan[SUP] 9 [/SUP], Gavin Washburn[SUP] 1 [/SUP], Monika Mis[SUP] 1 [/SUP], Devi Santhosh[SUP] 6 [/SUP], Sneha Somasekar[SUP] 10 [/SUP], G H Hiranjith[SUP] 1 [/SUP], Derek Vargas[SUP] 1 [/SUP], Sangeetha Mohan[SUP] 11 [/SUP], Sameer Phalke[SUP] 11 [/SUP], Boney Kuriakose[SUP] 12 [/SUP], Aju Antony[SUP] 11 [/SUP], Mart Ustav Jr[SUP] 5 [/SUP], Stephan C Schuster[SUP] 13 [/SUP], Sachdev Sidhu[SUP] 5 [/SUP], Jagath R Junutula[SUP] 6 [/SUP], Natalia Jura[SUP] 14 15 [/SUP], Somasekar Seshagiri[SUP] 16 17 [/SUP]



Affiliations

Abstract

COVID-19 is a respiratory illness caused by a novel coronavirus called SARS-CoV-2. The viral spike (S) protein engages the human angiotensin-converting enzyme 2 (ACE2) receptor to invade host cells with ~10-15-fold higher affinity compared to SARS-CoV S-protein, making it highly infectious. Here, we assessed if ACE2 polymorphisms can alter host susceptibility to SARS-CoV-2 by affecting this interaction. We analyzed over 290,000 samples representing >400 population groups from public genomic datasets and identified multiple ACE2 protein-altering variants. Using reported structural data, we identified natural ACE2 variants that could potentially affect virus-host interaction and thereby alter host susceptibility. These include variants S19P, I21V, E23K, K26R, T27A, N64K, T92I, Q102P and H378R that were predicted to increase susceptibility, while variants K31R, N33I, H34R, E35K, E37K, D38V, Y50F, N51S, M62V, K68E, F72V, Y83H, G326E, G352V, D355N, Q388L and D509Y were predicted to be protective variants that show decreased binding to S-protein. Using biochemical assays, we confirmed that K31R and E37K had decreased affinity, and K26R and T92I variants showed increased affinity for S-protein when compared to wildtype ACE2. Consistent with this, soluble ACE2 K26R and T92I were more effective in blocking entry of S-protein pseudotyped virus suggesting that ACE2 variants can modulate susceptibility to SARS-CoV-2.
 
Back
Top Bottom